Essais liés9clinical trials
VilleNew Yorklocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT02008357

Ouvrir le site du centre

Essais cliniques associés

9
MoléculeIndication / populationPhaseNCTTitreStatut
Photodynamic therapy-Photofrin Cancer Phase 3 NCT02082522 Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) TERMINATED
Low Dose Benfotiamine Alzheimer Phase 2 NCT06223360 A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) ACTIVE_NOT_RECRUITING
N-acetylcysteine Parkinson Phase 1/2 NCT01470027 NAC for PD — N-Acetylcysteine for Neuroprotection in Parkinson's Disease COMPLETED
Solanezumab Alzheimer Phase 3 NCT02008357 A4 — Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss COMPLETED
Trontinemab Alzheimer Phase 3 NCT07169578 TRONTIER 1 — A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease RECRUITING
Prasinezumab Parkinson Phase 3 NCT07174310 PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease RECRUITING
CC-97540 Lupus Phase 2 NCT07015983 A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) ACTIVE_NOT_RECRUITING
HBI-002 Parkinson Phase 2 NCT07005180 LoCaMoTE-PD — Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease RECRUITING
CVN424 75 mg Parkinson Phase 3 NCT06553027 To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications ACTIVE_NOT_RECRUITING